<table border="1" id="if8bc1032-f2cb-4912-8c6a-02eab1248163" width="801" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Subgroup Analyses of Mortality and Hospitalization During the First Two years Following Randomization</caption>
<tbody>
<tr>
<td> </td>
<td> </td>
<td>Risk of All-Cause Mortality or All-Cause Hospitalization*</td>
<td> </td>
<td> </td>
<td>Risk of HF-Related Mortality of HF-Related Hospitalization*</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> </td>
<td>n</td>
<td>Placebo</td>
<td>Digoxin</td>
<td>Relative Risk†</td>
<td>Placebo</td>
<td>Digoxin</td>
<td>Relative Risk†</td>
</tr>
<tr>
<td>All Patients <br/>(EF (0.45)</td>
<td>6801</td>
<td>604</td>
<td>593</td>
<td>0.94 (0.88-1.00)</td>
<td>294</td>
<td>217</td>
<td>0.69(0.63-0.76)</td>
</tr>
<tr>
<td>NYHA I/II</td>
<td>4571</td>
<td>549</td>
<td>541</td>
<td>0.96 (0.89-1.04)</td>
<td>242</td>
<td>178</td>
<td>0.70 (0.62-0.80)</td>
</tr>
<tr>
<td>EF 0.25-0.45</td>
<td>4543</td>
<td>568</td>
<td>571</td>
<td>0.99 (0.91-1.07)</td>
<td>244</td>
<td>190</td>
<td>0.74 (0.66-0.84)</td>
</tr>
<tr>
<td>CTR≤0.55</td>
<td>4455</td>
<td>561</td>
<td>563</td>
<td>0.98 (0.91-1.06)</td>
<td>239</td>
<td>180</td>
<td>0.71 (0.63-0.81)</td>
</tr>
<tr>
<td>NYHA<br/>III/IV</td>
<td>2224</td>
<td>719</td>
<td>696</td>
<td>0.88 (0.80-0.97)</td>
<td>402</td>
<td>295</td>
<td>0.65 (0.57-0.75)</td>
</tr>
<tr>
<td>EF less than 0.25</td>
<td>2258</td>
<td>677</td>
<td>637</td>
<td>0.84 (0.76-0.93)</td>
<td>394</td>
<td>270</td>
<td>0.61 (0.53-0.71)</td>
</tr>
<tr>
<td>CTR greater than 0.55</td>
<td>2346</td>
<td>687</td>
<td>650</td>
<td>0.85 (0.77-0.94)</td>
<td>398</td>
<td>287</td>
<td>0.65 (0.57-0.75)</td>
</tr>
<tr>
<td>EF greater than 0.45‡</td>
<td>987</td>
<td>571</td>
<td>585</td>
<td>1.04 (0.88-1.23)</td>
<td>179</td>
<td>136</td>
<td>0.72 (0.53-0.99)</td>
</tr>
</tbody>
</table>